Stay updated with breaking news from 37555810. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective reduced by equities research analysts at Maxim Group from $90.00 to $85.00 in a research note issued on Wednesday, Briefing.com reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price suggests a potential upside of 30.37% from […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price lowered by Royal Bank of Canada from $76.00 to $74.00 in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has a sector perform rating on the biopharmaceutical company’s stock. A number of other research analysts also recently issued reports […]
Cozad Asset Management Inc. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 69,658 shares of the biopharmaceutical company’s stock after selling 3,185 shares during the period. Cozad Asset Management Inc.’s holdings […]
Cozad Asset Management Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,658 shares of the biopharmaceutical company’s stock after selling 3,185 shares during […]
Valmark Advisers Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 14.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,236 shares of the biopharmaceutical company’s stock after selling 726 shares during the period. Valmark Advisers […]